Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls
About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Dersch, R. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury - Klimaschewski, Lars ELSEVIER, 2016, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:10 ; year:2019 ; number:1 ; pages:166-169 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ttbdis.2018.09.011 |
|---|
| Katalog-ID: |
ELV044907680 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV044907680 | ||
| 003 | DE-627 | ||
| 005 | 20230624112830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181123s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ttbdis.2018.09.011 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica |
| 035 | |a (DE-627)ELV044907680 | ||
| 035 | |a (ELSEVIER)S1877-959X(18)30317-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 333.7 |a 690 |q VZ |
| 084 | |a 48.00 |2 bkl | ||
| 100 | 1 | |a Dersch, R. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls |
| 264 | 1 | |c 2019 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. | ||
| 650 | 7 | |a Lyme disease |2 Elsevier | |
| 650 | 7 | |a Immunoblot |2 Elsevier | |
| 650 | 7 | |a Comparison |2 Elsevier | |
| 650 | 7 | |a Line immunoblot |2 Elsevier | |
| 650 | 7 | |a Lyme neuroborreliosis |2 Elsevier | |
| 650 | 7 | |a Follow-up |2 Elsevier | |
| 700 | 1 | |a Sarnes, A. |4 oth | |
| 700 | 1 | |a Maul, M. |4 oth | |
| 700 | 1 | |a Minakowski, O. |4 oth | |
| 700 | 1 | |a Hottenrott, T. |4 oth | |
| 700 | 1 | |a Stich, O. |4 oth | |
| 700 | 1 | |a Rauer, S. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Klimaschewski, Lars ELSEVIER |t siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019356773 |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:1 |g pages:166-169 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ttbdis.2018.09.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-FOR | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 48.00 |j Land- und Forstwirtschaft: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 |e 1 |h 166-169 |g 4 | ||
| author_variant |
r d rd |
|---|---|
| matchkey_str |
derschrsarnesamaulmminakowskiohottenrott:2019----:muolteciiytolwpnraeptetwtlmnuoorl |
| hierarchy_sort_str |
2019 |
| bklnumber |
48.00 |
| publishDate |
2019 |
| allfields |
10.1016/j.ttbdis.2018.09.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica (DE-627)ELV044907680 (ELSEVIER)S1877-959X(18)30317-0 DE-627 ger DE-627 rakwb eng 610 VZ 333.7 690 VZ 48.00 bkl Dersch, R. verfasserin aut Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up Elsevier Sarnes, A. oth Maul, M. oth Minakowski, O. oth Hottenrott, T. oth Stich, O. oth Rauer, S. oth Enthalten in Elsevier Klimaschewski, Lars ELSEVIER siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury 2016 Amsterdam [u.a.] (DE-627)ELV019356773 volume:10 year:2019 number:1 pages:166-169 extent:4 https://doi.org/10.1016/j.ttbdis.2018.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR GBV_ILN_70 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 10 2019 1 166-169 4 |
| spelling |
10.1016/j.ttbdis.2018.09.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica (DE-627)ELV044907680 (ELSEVIER)S1877-959X(18)30317-0 DE-627 ger DE-627 rakwb eng 610 VZ 333.7 690 VZ 48.00 bkl Dersch, R. verfasserin aut Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up Elsevier Sarnes, A. oth Maul, M. oth Minakowski, O. oth Hottenrott, T. oth Stich, O. oth Rauer, S. oth Enthalten in Elsevier Klimaschewski, Lars ELSEVIER siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury 2016 Amsterdam [u.a.] (DE-627)ELV019356773 volume:10 year:2019 number:1 pages:166-169 extent:4 https://doi.org/10.1016/j.ttbdis.2018.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR GBV_ILN_70 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 10 2019 1 166-169 4 |
| allfields_unstemmed |
10.1016/j.ttbdis.2018.09.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica (DE-627)ELV044907680 (ELSEVIER)S1877-959X(18)30317-0 DE-627 ger DE-627 rakwb eng 610 VZ 333.7 690 VZ 48.00 bkl Dersch, R. verfasserin aut Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up Elsevier Sarnes, A. oth Maul, M. oth Minakowski, O. oth Hottenrott, T. oth Stich, O. oth Rauer, S. oth Enthalten in Elsevier Klimaschewski, Lars ELSEVIER siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury 2016 Amsterdam [u.a.] (DE-627)ELV019356773 volume:10 year:2019 number:1 pages:166-169 extent:4 https://doi.org/10.1016/j.ttbdis.2018.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR GBV_ILN_70 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 10 2019 1 166-169 4 |
| allfieldsGer |
10.1016/j.ttbdis.2018.09.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica (DE-627)ELV044907680 (ELSEVIER)S1877-959X(18)30317-0 DE-627 ger DE-627 rakwb eng 610 VZ 333.7 690 VZ 48.00 bkl Dersch, R. verfasserin aut Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up Elsevier Sarnes, A. oth Maul, M. oth Minakowski, O. oth Hottenrott, T. oth Stich, O. oth Rauer, S. oth Enthalten in Elsevier Klimaschewski, Lars ELSEVIER siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury 2016 Amsterdam [u.a.] (DE-627)ELV019356773 volume:10 year:2019 number:1 pages:166-169 extent:4 https://doi.org/10.1016/j.ttbdis.2018.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR GBV_ILN_70 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 10 2019 1 166-169 4 |
| allfieldsSound |
10.1016/j.ttbdis.2018.09.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica (DE-627)ELV044907680 (ELSEVIER)S1877-959X(18)30317-0 DE-627 ger DE-627 rakwb eng 610 VZ 333.7 690 VZ 48.00 bkl Dersch, R. verfasserin aut Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up Elsevier Sarnes, A. oth Maul, M. oth Minakowski, O. oth Hottenrott, T. oth Stich, O. oth Rauer, S. oth Enthalten in Elsevier Klimaschewski, Lars ELSEVIER siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury 2016 Amsterdam [u.a.] (DE-627)ELV019356773 volume:10 year:2019 number:1 pages:166-169 extent:4 https://doi.org/10.1016/j.ttbdis.2018.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR GBV_ILN_70 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 10 2019 1 166-169 4 |
| language |
English |
| source |
Enthalten in siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury Amsterdam [u.a.] volume:10 year:2019 number:1 pages:166-169 extent:4 |
| sourceStr |
Enthalten in siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury Amsterdam [u.a.] volume:10 year:2019 number:1 pages:166-169 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Land- und Forstwirtschaft: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Lyme disease Immunoblot Comparison Line immunoblot Lyme neuroborreliosis Follow-up |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury |
| authorswithroles_txt_mv |
Dersch, R. @@aut@@ Sarnes, A. @@oth@@ Maul, M. @@oth@@ Minakowski, O. @@oth@@ Hottenrott, T. @@oth@@ Stich, O. @@oth@@ Rauer, S. @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV019356773 |
| dewey-sort |
3610 |
| id |
ELV044907680 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV044907680</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624112830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181123s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ttbdis.2018.09.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV044907680</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1877-959X(18)30317-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">48.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dersch, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lyme disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunoblot</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Comparison</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Line immunoblot</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lyme neuroborreliosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Follow-up</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sarnes, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maul, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Minakowski, O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hottenrott, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stich, O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rauer, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Klimaschewski, Lars ELSEVIER</subfield><subfield code="t">siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019356773</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:166-169</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ttbdis.2018.09.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">48.00</subfield><subfield code="j">Land- und Forstwirtschaft: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="h">166-169</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| author |
Dersch, R. |
| spellingShingle |
Dersch, R. ddc 610 ddc 333.7 bkl 48.00 Elsevier Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls |
| authorStr |
Dersch, R. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019356773 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 333 - Economics of land & energy 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 333.7 690 VZ 48.00 bkl Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up Elsevier |
| topic |
ddc 610 ddc 333.7 bkl 48.00 Elsevier Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up |
| topic_unstemmed |
ddc 610 ddc 333.7 bkl 48.00 Elsevier Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up |
| topic_browse |
ddc 610 ddc 333.7 bkl 48.00 Elsevier Lyme disease Elsevier Immunoblot Elsevier Comparison Elsevier Line immunoblot Elsevier Lyme neuroborreliosis Elsevier Follow-up |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a s as m m mm o m om t h th o s os s r sr |
| hierarchy_parent_title |
siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury |
| hierarchy_parent_id |
ELV019356773 |
| dewey-tens |
610 - Medicine & health 330 - Economics 690 - Building & construction |
| hierarchy_top_title |
siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV019356773 |
| title |
Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls |
| ctrlnum |
(DE-627)ELV044907680 (ELSEVIER)S1877-959X(18)30317-0 |
| title_full |
Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls |
| author_sort |
Dersch, R. |
| journal |
siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury |
| journalStr |
siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
166 |
| author_browse |
Dersch, R. |
| container_volume |
10 |
| physical |
4 |
| class |
610 VZ 333.7 690 VZ 48.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Dersch, R. |
| doi_str_mv |
10.1016/j.ttbdis.2018.09.011 |
| dewey-full |
610 333.7 690 |
| title_sort |
immunoblot reactivity at follow-up in treated patients with lyme neuroborreliosis and healthy controls |
| title_auth |
Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls |
| abstract |
About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. |
| abstractGer |
About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. |
| abstract_unstemmed |
About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR GBV_ILN_70 |
| container_issue |
1 |
| title_short |
Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls |
| url |
https://doi.org/10.1016/j.ttbdis.2018.09.011 |
| remote_bool |
true |
| author2 |
Sarnes, A. Maul, M. Minakowski, O. Hottenrott, T. Stich, O. Rauer, S. |
| author2Str |
Sarnes, A. Maul, M. Minakowski, O. Hottenrott, T. Stich, O. Rauer, S. |
| ppnlink |
ELV019356773 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.ttbdis.2018.09.011 |
| up_date |
2024-07-06T22:43:13.353Z |
| _version_ |
1803871367571963904 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV044907680</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624112830.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181123s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ttbdis.2018.09.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001263.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV044907680</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1877-959X(18)30317-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">48.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dersch, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunoblot reactivity at follow-up in treated patients with Lyme neuroborreliosis and healthy controls</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">About 5–20% of the general population in endemic areas have seroprevalence for anti-borrelial antibodies. Previous studies have shown a high rate of 25–97% of persisting anti-borrelial antibodies in patients with treated Lyme neuroborreliosis (LNB) at follow-up. These studies used immunoblots with antigens from whole-cell sonicates, which could be less specific than modern recombinant antigens. We assessed the seroprevalence of anti-borrelial antibodies in serum from patients with definite LNB and healthy controls with a line immunoblot using highly specific recombinant antigens.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lyme disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunoblot</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Comparison</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Line immunoblot</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lyme neuroborreliosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Follow-up</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sarnes, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maul, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Minakowski, O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hottenrott, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stich, O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rauer, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Klimaschewski, Lars ELSEVIER</subfield><subfield code="t">siRNA mediated down-regulation of Sprouty2/4 diminishes ischemic brain injury</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019356773</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:166-169</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ttbdis.2018.09.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">48.00</subfield><subfield code="j">Land- und Forstwirtschaft: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="h">166-169</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.399708 |